Vol 13, No 2 (April 30, 2024): Chinese Clinical Oncology

Editorial

New surgical strategies from endoscopical resection to liver transplantation for hepatobiliopancreatic tumours
Giovanni Battista Levi Sandri
Chinese Clinical Oncology  
2024;
13
(2)
:18
.

Original Article

Anaerobic gram-negative rod bacteremia as a marker of gastrointestinal cancer in Japanese patients: a single-center retrospective study
Eiko Abe, Kazuhiro Ishikawa, Kazunari Onishi, Nobuyoshi Mori
Chinese Clinical Oncology  
2024;
13
(2)
:19
.
Intralesional curettage and surgical adjuvants in the treatment of giant cell tumor of bone: meta-analysis and systematic review
Ao Leng, Haojie Gao, Jiacheng Li, Lingzhi Meng, Qi Wang, Liangbi Xiang
Chinese Clinical Oncology  
2024;
13
(2)
:20
.
Stepwise analysis of thyroid diagnostic modalities with genomic imprinting detection
Wanting Yang, Ming Yin, Jiehong Zhou, Yun Zhu, Beibei Ye, Hui Shi, Bingjie Zhang, Can Yue, Yifeng Zhang, Hongxun Wu, Haohao Li, Xuliang Xia, Shufang Yang, Buyun Ma
Chinese Clinical Oncology  
2024;
13
(2)
:21
.
Adjuvant radiotherapy versus observation after gross total resection of WHO grade II ependymoma: a systematic review and individual-participant data meta-analysis
Yilong Zheng, Shi Hui Ong, Vincent Diong Weng Nga, Balamurugan Vellayappan
Chinese Clinical Oncology  
2024;
13
(2)
:22
.

Review Article

Narrative review of the utility of magnetic resonance imaging in radiotherapy for cervical cancer
Jiwoo Lee, Carminia Lapuz, Richard Khor, Eddie Lau, Natalie Yang, Adeline Lim, Farshad Foroudi, Sweet Ping Ng
Chinese Clinical Oncology  
2024;
13
(2)
:23
.
Advancements and future directions in positron emission tomography-guided radiotherapy: a narrative review
Shahil Mehta, Christine Yang, Hossein Jadvar, Patrick M. Colletti, Peter S. Conti, Lijun Ma, Eric L. Chang, Jason C. Ye
Chinese Clinical Oncology  
2024;
13
(2)
:24
.
Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review
Jin Y. Chang, Samantha M. Ruff, Jordan M. Cloyd
Chinese Clinical Oncology  
2024;
13
(2)
:25
.
Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review
Tianming Wang, Liang Zhang, Ying Cheng
Chinese Clinical Oncology  
2024;
13
(2)
:26
.

Editorial Commentary

Triplet therapy for metastatic hormone sensitive prostate cancer—looking beyond volume of disease
Jenny Peng, Srikala S. Sridhar, Di Maria Jiang
Chinese Clinical Oncology  
2024;
13
(2)
:27
.
Oligometastatic disease: a need for consensus to cure the incurable in a multidisciplinary approach
Sergio Martinez-Recio, Andres Barba, Nuria Farré, Margarita Majem
Chinese Clinical Oncology  
2024;
13
(2)
:28
.
Radiation-free conditioning in acute lymphoblastic leukemia: is it time?
Manuel Espinoza-Gutarra, Razan Mohty, Omer Jamy
Chinese Clinical Oncology  
2024;
13
(2)
:29
.
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer
Nicole Conci, Andrea De Giglio, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino
Chinese Clinical Oncology  
2024;
13
(2)
:30
.
CAR-T cell therapy: unravelling its potential in extra-nodal diffuse large B cell lymphoma
Salman J. Khan, Muhamad Alhaj Moustafa
Chinese Clinical Oncology  
2024;
13
(2)
:31
.